周边动脉疾病市场规模、份额和成长分析（按类型、治疗方法、疾病、给药途径、最终用户和地区划分）—2026-2033年产业预测

预计到 2024 年，周边动脉疾病(PAD) 市场规模将达到 58.5 亿美元，到 2025 年将成长至 64.6 亿美元，到 2033 年将成长至 142.5 亿美元，在预测期（2026-2033 年）内，复合成长率为 10.4%。

市场调查显示，美国约有650万40岁以上族群患有周边动脉疾病（PAD），男女均有患病，但非裔美国人的发生率明显较高。人口老化是PAD盛行率上升的关键因素，因为血管疾病的风险会随着老龄化的增长而增加。此外，除了人口结构的变化，PAD诊断和治疗方案的技术创新和核准也在不断增长。这些因素共同加剧了周边动脉疾病的整体风险。人口老化、疾病发生率上升以及技术进步的结合，凸显了美国医疗保健市场中与PAD相关的复杂且不断变化的风险因素。

周边动脉疾病市场驱动因素

老年族群中糖尿病和高血压盛行率的不断上升是周边动脉疾病（PAD）市场成长的关键驱动因素。老年人发生血管併发症的风险尤其高，而这些慢性疾病的存在会显着增加PAD的风险。糖尿病和高血压会加速动脉狭窄和硬化，严重限制流向四肢的血液。因此，这些健康问题在老龄化人口中的日益增多直接影响着市场动态，并催生了对有效PAD治疗方法和干预措施日益增长的需求。

周边动脉疾病市场限制因素

周边动脉疾病(PAD) 的復发对其市场成长潜力构成重大挑战。儘管治疗方案不断改进，但 PAD 復发的风险仍阻碍着市场的永续发展。此外，产业内的产品召回问题会进一步加剧这些挑战。召回会削弱消费者信心，引起监管机构的关注，并需要采取纠正措施，这可能会阻碍整体市场的成长和稳定。为了有效克服这些障碍，相关人员必须携手合作，共同应对与疾病管理和产品安全相关的复杂挑战，从而促进周边动脉疾病治疗方案的持续进步。

周边动脉疾病（PAD）市场趋势

周边动脉疾病(PAD) 市场呈现显着上升趋势，主要受疾病发生率上升和创新产品核准增加的推动。 PAD 病例激增凸显了对先进诊断和治疗方案的需求，从而推动了市场成长。医疗技术的不断进步为应对 PAD 的多重挑战开闢了新的解决方案，有助于改善患者照护和治疗效果。此外，随着监管机构不断核准突破性疗法，市场有望充分利用这些进展，为相关人员和医疗服务提供者创造一个繁荣的市场环境。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二手资料和一手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2025）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析

全球周边动脉疾病市场规模（按类型及复合年增长率划分）（2026-2033 年）

• 週边血管血管成形术用气球
• 斑块调节装置
• 外周支架
• 週边导管
• 血流调节装置
• 下腔静脉（IVC）过滤器
• 末梢用配件

全球周边动脉疾病市场规模（按治疗方法和复合年增长率划分）（2026-2033 年）

• 装置
  • 支架
  • 气球
  • 动脉粥状硬化斑块切除术装置
• 导管
  • 药物释放型导管
  • 球囊导管
  • 导管导引线
• 斑块修饰装置
• 血流调节装置
• 其他的

全球周边动脉疾病市场规模（按疾病类型和复合年增长率划分）（2026-2033 年）

• 降血脂药物
• 三重H疗法
• 血糖调节器
• 血栓预防
• 强心剂
• 溶栓剂
• 抗发炎药

全球周边动脉疾病市场规模（依给药途径及复合年增长率划分）（2026-2033 年）

• 口服
• 肠外给药
• 其他的

全球周边动脉疾病市场规模（依最终用户划分）及复合年增长率（2026-2033 年）

• 医院和诊所
• 门诊手术诊所

全球周边动脉疾病市场规模及复合年增长率（2026-2033）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2023-2025年营收年比比较

主要企业简介

• Medtronic plc（Ireland）
• Abbott Laboratories（USA）
• Boston Scientific Corporation（USA）
• Becton, Dickinson and Company（BD）（USA）
• Philips（Netherlands）
• Terumo Corporation（Japan）
• Cook Medical（USA）
• Cardinal Health, Inc.（USA）
• B. Braun Melsungen AG（Germany）
• Getinge AB（Sweden）
• Merit Medical Systems, Inc.（USA）
• BIOTRONIK SE & Co. KG（Germany）
• Endologix, Inc.（USA）
• Gore Medical（USA）
• Penumbra, Inc.（USA）
• AngioDynamics, Inc.（USA）
• Johnson & Johnson（USA）
• Bayer AG（Germany）

结论与建议

Peripheral Artery Disease Market size was valued at USD 5.85 Billion in 2024 and is poised to grow from USD 6.46 Billion in 2025 to USD 14.25 Billion by 2033, growing at a CAGR of 10.4% during the forecast period (2026-2033).

Market insights reveal that around 6.5 million individuals aged 40 and older in the U.S. are impacted by Peripheral Artery Disease (PAD), affecting both genders with a notably higher incidence among African Americans. The aging population plays a critical role in the growing prevalence of PAD, as the risk of vascular diseases increases with age. Furthermore, the demographic shift is paralleled by a rise in innovations and approvals for diagnostics and treatment solutions for PAD. These elements converge to enhance the overall risk landscape for peripheral arterial disease. The combination of an aging populace, increasing disease rates, and technological advancements highlights the complex and evolving risk factors associated with PAD in the U.S. healthcare market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Peripheral Artery Disease market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Peripheral Artery Disease Market Segments Analysis

Global Peripheral Artery Disease Market is segmented by Type, Treatment, Disease, Route of Administration, End User and region. Based on Type, the market is segmented into Peripheral Angioplasty Balloons, Plaque Modification Devices, Peripheral Stents, Peripheral Catheters, Hemodynamic Flow Alteration Devices, Inferior Vena Cava (IVC) Filters and Peripheral Accessories. Based on Treatment, the market is segmented into Device, Catheters, Plaque Modification Devices, Hemodynamic Flow Alteration Devices and Others. Based on Disease, the market is segmented into Lipid Lowering Drugs, Triple-H Therapy, Glucose Regulating Drugs, Blood Clot Preventing Drugs,, Inotropes,, Thrombolytic Agents, and Anti-Inflammatory Agents. Based on Route of Administration, the market is segmented into Oral, Parenteral and Others. Based on End User, the market is segmented into Hospitals & Clinics and Ambulatory Surgical Clinics. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Peripheral Artery Disease Market

The rising prevalence of elderly individuals affected by diabetes and hypertension is a crucial driving force behind the growth of the peripheral artery disease (PAD) market. Older adults are especially vulnerable to vascular complications, and the presence of these chronic conditions significantly heightens the risk of developing PAD. Diabetes and high blood pressure contribute to the narrowing and hardening of arteries, which severely restricts blood flow to the limbs. As a result, the increasing incidence of these health issues within the aging population is directly influencing market dynamics and creating a heightened demand for effective PAD treatments and interventions.

Restraints in the Peripheral Artery Disease Market

The recurring nature of peripheral artery disease (PAD) poses a significant challenge to the market's growth potential. Despite improvements in treatment options, the risk of PAD reappearing continues to hinder sustained market progression. Additionally, issues surrounding product recalls in the industry may further exacerbate these challenges. Such recalls can undermine consumer confidence, draw regulatory attention, and necessitate remedial actions, all of which can stifle overall market growth and stability. To effectively navigate these obstacles, stakeholders must collaboratively address the intricate issues related to managing the disease and ensuring product safety, thereby fostering ongoing advancements in solutions for peripheral artery disease.

Market Trends of the Peripheral Artery Disease Market

The Peripheral Artery Disease (PAD) market is witnessing a notable upward trend driven by the rising incidence of the condition alongside an influx of innovative product approvals. This surge in PAD cases underscores the demand for advanced diagnostic and therapeutic options, catalyzing market growth. The ongoing advancements in medical technologies are paving the way for new solutions that address the multifaceted challenges of PAD, enhancing patient care and outcomes. Furthermore, as regulatory bodies continue to endorse groundbreaking treatments, the market is expected to capitalize on these developments, fostering a landscape rich in opportunities for stakeholders and healthcare providers alike.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Peripheral Artery Disease Market Size by Type & CAGR (2026-2033)

• Market Overview
• Peripheral Angioplasty Balloons
• Plaque Modification Devices
• Peripheral Stents
• Peripheral Catheters
• Hemodynamic Flow Alteration Devices
• Inferior Vena Cava (IVC) Filters
• Peripheral Accessories

Global Peripheral Artery Disease Market Size by Treatment & CAGR (2026-2033)

• Market Overview
• Device
  • Stents
  • Balloons
  • Atherectomy Devices
• Catheters
  • Drug-Eluting Catheters
  • Balloon Catheters
  • Guidewires
• Plaque Modification Devices
• Hemodynamic Flow Alteration Devices
• Others

Global Peripheral Artery Disease Market Size by Disease & CAGR (2026-2033)

• Market Overview
• Lipid Lowering Drugs
• Triple-H Therapy
• Glucose Regulating Drugs
• Blood Clot Preventing Drugs,
• Inotropes,
• Thrombolytic Agents,
• Anti-Inflammatory Agents

Global Peripheral Artery Disease Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Oral
• Parenteral
• Others

Global Peripheral Artery Disease Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals & Clinics
• Ambulatory Surgical Clinics

Global Peripheral Artery Disease Market Size & CAGR (2026-2033)

• North America (Type, Treatment, Disease, Route of Administration, End User)
  • US
  • Canada
• Europe (Type, Treatment, Disease, Route of Administration, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Treatment, Disease, Route of Administration, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Treatment, Disease, Route of Administration, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Treatment, Disease, Route of Administration, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Medtronic plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boston Scientific Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton, Dickinson and Company (BD) (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Philips (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Terumo Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cook Medical (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cardinal Health, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• B. Braun Melsungen AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Getinge AB (Sweden)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merit Medical Systems, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BIOTRONIK SE & Co. KG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Endologix, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gore Medical (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Penumbra, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AngioDynamics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations